Anchored in a unique, patented metabolomic signature technology designed to enable rapid detection and identification of microorganisms as they grow in culture, Specific Diagnostics has developed an in vitro diagnostic system. The firm's first commercial application applies this fundamental new capability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies may require up to three days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than ONE day. Specificâs Reveal⢠instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specificâs unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specificâs system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing. In April 2022 it was announced that bioMérieux - leader in the field of in vitro diagnostics - had acquired Specific Diagnostics. bioMérieux had held a minority stake in Specific Diagnostics since 2019, and the two firms had signed a co-distribution agreement covering the European market
